TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed advanced, recurrent or metastatic adenocarcinoma of stomach (stage IV by primary tumor, regional nodes, metastasis(TNM) staging system)~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* More than 3 months expected life span~* Measurable lesion by RECIST criteria version 1.1~* Palliative chemotherapy naive~* Adequate organ functions~* Participants must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital~Exclusion Criteria:~* Positive Her2 status on participants' cancer tissue.~* Any prior 2 years or concurrent malignancy other than non-melanoma skin cancer, in situ cancer of uterine cervix, or papillary or follicular thyroid cancer.~* Participants who had received radiation therapy for target lesions 4 weeks before study enrollment~* Participants who had received major surgery 4 weeks before study enrollment~* Participants with active infection, severe heart disease, uncontrollable hypertension or diabetes mellitus, myocardial infarction during the preceding 12 months, pregnancy, or breast feeding~* Participants with central nervous system(CNS) metastases~* Participants with peripheral sensory neuropathies with impaired functional activities~* Participants with gastrointestinal obstruction or bleeding inducing mal-absorption of oral chemotherapeutic agents.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oxaliplatin, Irinotecan, S-1(OIS) (Type: EXPERIMENTAL): triple combination with oxaliplatin, irinotecan, and S-1.~Treatment will be delivered as a 2-week cycle.~1. Oxaliplatin 65 mg/m2 iv on day 1~2. Irinotecan 135 mg/m2 iv on day 1~3. S-1 80 mg/m2/day on day 1-7

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients transplanted in the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran.~Exclusion Criteria:~* Allergy to Fosfomycin disodium or Trimethoprim / Sulfamethoxazole

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fosfomycin disodium (Type: EXPERIMENTAL): * Fosfomycin disodium 4 g intravenously: 3 hours before kidney transplant surgery, 3 hours before urinary catheter removal and 3 hours prior to ureteral catheter removal.~* Trimethoprim / Sulfamethoxazole (160/800 mg) 1 tablet orally every 24 hours.
- Trimethoprim / Sulfamethoxazole (Type: ACTIVE_COMPARATOR): * Trimethoprim / Sulfamethoxazole (160/800 mg) 1 tablet orally every 24 hours.~* Intravenous placebo solution at the same time of application of fosfomycin disodium in the experimental arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Established diagnosis of Multiple Sclerosis~* Age: 18 - 70 years~* Indication for vaccination (according to public recommendation)~* Written informed consent~Exclusion Criteria:~* Current relapse of MS~* Unstable disease~* Contraindication for vaccination (acute infection, fever, allergy to vaccine)~* Unable to comply with study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fluoxetine on Motor Rehabilitation After Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged from 18 to 85~* No motor relapse from a previous stroke~* Inclusion from day 5 to day 10 after stroke~* Ischemic stroke with unilateral motor deficit~* Motor NIHSS ≥ 5 on the affected side of the body~* NIHSS \< 20~* Fugl Meyer Motor Scale \<55~* Modified Rankin Scale between 1 and 5~* Informed consent obtained from the subject or a member of his family~Exclusion Criteria:~* Pregnant or breast-feeding woman~* Woman able to procreate without valid contraception~* Subject protected by law~* Concomitant disease with unfavourable prognosis within 1 year~* Drug addiction~* Allergy to fluoxetine~* Hepatic failure (TGO and TGP \>2N)~* Permanent Renal failure (Creatinin \>180micromol/l)~* Patients treated by tricyclic antidepressant, selective serotonin reuptake inhibitor, monoamine oxidase inhibitor (IMAO), and neuroleptics in the past month~* Depression requiring pharmacological treatment~* Previous stroke with motor relapse~* Fugl Meyer Motor Scale \> 55~* Modified Rankin Scale = 0 or 6~* Patients needing carotid surgery within 3 months~* Aphasia preventing correct evaluation of motor and depression scales.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): fluoxetine
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV Positive~* On HAART, with plasma viral load \< 50 copies/ml for previous 12 months or more~* Able to provide informed consent~* HAND diagnosis, with symptom progression within previous 6 months~Exclusion Criteria:~* Non-HIV related neurological disorders and active central nervous system (CNS) opportunistic infection (as assessed by full blood count, electrolytes, creatinine, glucose, liver funciton tests, cryptococcal antigen, venereal disease research laboratory (VDRL), MRI brain scan and CSF analysis for cell count, protein, glucose, culture, VDRL and cryptococcal antigen)~* Psychiatric disorders on the psychiatric axis~* Current major depression~* Current substance use disorder, or severe substance use disorder within 12 months of study entry~* Active Hepatitis C Virus (HCV) (detectable HCV RNA)~* History of loss of consciousness \> 1 hour~* Non-proficient in English~* Medications known to pharmacologically interact with antiretrovirals (ARVs)~* Currently taking an entry inhibitor~* Pregnancy (as assessed by the urine pregnancy test)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of care HAART regimen (Type: NO_INTERVENTION): Participants randomised to this arm of the trial will remain on their usual prescribed HAART regimen.
- Maraviroc (Type: EXPERIMENTAL): Participants randomised to this arm will remain on their usual prescribed HAART regimen, with the addition of Maraviroc. Maraviroc will be prescribed according to the Product Information Sheet, with consideration given to background therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on NT-PRO BNP in Type 2 Diabetics With Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age\>30 and age\<70, urinary albumin excretion (UAE) ≥150 mg/24 h~Exclusion Criteria:~* any infectious or malignant diseases, non-diabetic kidney disease, retinal hemorrhage, acute myocardial infarction, uncontrolled hypertension, pregnancy, unable to follow up, hyperthyroidism, baseline serum potassium concentrations ≥5.5 meq/L, glomerular filtration rate (GFR)\<30mL/min/1.73 m and intolerance of pentoxifylline

- Gender: ALL
- Minimum Age: 38 Years
- Maximum Age: 76 Years
- Healthy Volunteers: f

Study Arms:
- pentoxifylline & losartan (Type: ACTIVE_COMPARATOR): pentoxifylline arm took 400 mg pentoxifylline twice daily plus 50mg losartan daily for 12 weeks.
- Losartan (Type: ACTIVE_COMPARATOR): losartan arm took 100mg losartan daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of primary or de novo MDS using WHO classification~* Non-del(5q) low or Intermediate-1risk MDS~* ECOG performance status of 0-1~* Documented significant cytopenia for at least 2 months~* Must have discontinued growth factors (EPO, G-CSF, GM-CSF) for at least 21 days prior to study entry~* All study participants must be registered into the mandatory RevAssist® program and be willing and able to comply with the requirements of RevAssist®~* Females of childbearing potential should have two negative serum pregnancy tests with a sensitivity of at least 50 mIU/mL. The first test should be performed within 10-14 days, and the second test within 24 hours of prescribing lenalidomide (prescriptions must be filled within seven days)~Exclusion Criteria:~* Known hypersensitivity to Telintra™ (intravenous or oral)~* Known prior therapy with or hypersensitivity to thalidomide or lenalidomide~* Prior allogenic bone marrow transplant for MDS~* History or prior malignancy~  * Except for treated carcinoma of uterine cervix, basal cell or squamous cell skin cancer, or other cancers (e.g. breast, prostate) for which patient has been disease-free for at least 3 years.~* MDS evolving from:~  * A pre-existing myeloproliferative disorder~ * An autoimmune disease~ * Secondary to prior treatment with radiation or chemotherapy~* History of MDS IPSS score\>1.0~* Pregnant or lactating women~* Leptomeningeal or leukemic meningitis~* Prior treatment with DNA methyltransferase inhibitors (DMTI) \[e.g., azacitadine, decitabine, etc.\]

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Revlimid® in Combination with Telintra ® (Type: EXPERIMENTAL): Lenalidomide (Revlimid®) followed by Telintra® until MDS progression or lack of efficacy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy proven prostate cancer~* Negative bone scan~* Lymph nodes by CT or MRI~* Adequate blood work~* Performance Status - ECOG 0-1~* Life expectancy of at least 10 years~* \>40 years of age~Exclusion Criteria:~* Prior history of malignancy~* Prior hormonal therapy or chemotherapy~* Prior pelvic radiation therapy~* Unable to tolerate lying still 5-10 minutes/day

- Gender: MALE
- Minimum Age: 41 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment 1 (Type: ACTIVE_COMPARATOR): External beam radiation therapy + 6 months total androgen ablation
- Treatment 2 (Type: ACTIVE_COMPARATOR): External beam radiation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Dexmedetomidine on Cardiac Electrophysiology in Patients Under General Anesthesia During Perioperative Period

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Ages ranged from 18 to 65~* ASA I\~II~* patients undergoing elective general anesthesia~* the surgery time for 1\~3 h~Exclusion Criteria:~* Preoperative ECG abnormalities, including QTc ≥440 ms (male), 460ms (female)~* abnormal cardiac conduction, prolonged QT syndrome~* heart disease history, such as pacemaker implantation, unstable angina, congestive heart failure, Heart valve disease~* antiarrhythmic drugs (β-receptor blockers, calcium channel blockers, tricyclic antidepressants, etc.) that can prolong the QT interval taken within one week before surgery~* coronary heart disease, non-sinus Heart rhythm, bradycardia, tachycardia, other arrhythmia, etc~* intraoperative HR≤45 beats/min and need drugs to increase heart rate~* previous allergy to dexmedetomidine~* preoperative electrolyte abnormalities~* emergency surgery, neurological or mental disorders , Liver and kidney dysfunction~* patients who use analgesic pumps after surgery~* refusal of patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg (Type: EXPERIMENTAL): 10 min before induction of anesthesia,the loading dose of dexmedetomidine is 0.5 μg/kg, and completed in 10 minutes. The maintenance dose is 0.5 μg/kg per hour during the operation until 0.5 h before the operation finished.
- Loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg (Type: EXPERIMENTAL): 10 min before induction of anesthesia,the loading dose of dexmedetomidine is 1 μg/kg, and completed in 10 minutes. The maintenance dose is 0.5 μg/kg per hour during the operation until 0.5 h before the surgery finished.
- Loading dose with 1 μg/kg, maintenance dose with 1 μg/kg (Type: EXPERIMENTAL): 10 min before induction of anesthesia,the loading dose of dexmedetomidine is 1 μg/kg, and completed in 10 minutes. The maintenance dose is 1 μg/kg per hour during the operation until 0.5 h before the surgery finished.
- Normal saline (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Avoid DeliVering TherApies for Non-sustained Arrhythmias in ICD PatiEnts III

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Either ICD or CRT+ICD indications (Class I-IIA) according to the current AHA / ACC / ESC guidelines.~* Previous implant of a Medtronic device including ATP During Charging feature for 15 days at the maximum.~Exclusion Criteria:~* ICD replacements and upgrading.~* Brugada Syndrome, Long QT and HCM patients~* Ventricular tachyarrhythmia associated with reversible cause.~* Other electrical implantable devices (Neurostimulators, etc.).~* Subject's life expectancy less than 1 year.~* Subject on heart transplant list which is expected in less than 1 year.~* Subject is \<18 years of age, or the subject is under a minimum age that is required as defined by local law~* Women who are pregnant or women of childbearing potential who are not on a reliable form of birth control.~* Unwillingness or inability to provide written informed consent.~* Enrolment in, or intention to participate in, another clinical trial.~* Inaccessibility to come to the study center for the follow-up visits.~* Mechanical tricuspid valve.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Long NID (Type: EXPERIMENTAL): Programming a number of 30 out of 40 intervals to detect (NID)ventricular arrhythmia
- Short NID (Type: ACTIVE_COMPARATOR): Programming a number of 18 out of 24 intervals to detect (NID)ventricular arrhythmia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Risk Stratification Procedure for Thromboembolism Prophylaxis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or Female patients who are planned for elective TKR surgery (primary only).~2. Agreed to sign the Informed consent form (ICF).~3. Patients aged older than 18 years.~Exclusion Criteria:~1. Patients receiving anticoagulant for treatment.~2. Patients with a history of DVT or PE were excluded from the study due to the marked increase in the risk of recurrent VTE compared to the general risk of (7% vs. 0.1%); (Fahrni, 2015).~3. Patients with renal or hepatic failure, renal failure is defined as end-stage kidney disease (on dialysis); hepatic failure is defined as complete liver cirrhosis.~4. Pregnant woman.~5. Revision surgeries.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): In this group a VTE risk stratification procedure will be used
- Group B (Type: NO_INTERVENTION): In this group a standard VTE risk stratification procedure will be used (Caprini VTE risk assessment tool)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neuropathic Pain Syndrome Patient Study (MK-0000-072)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has moderate to severe nerve pain due to one of the following conditions: Postherpetic neuralgia, Painful diabetic neuropathy, Small fiber neuropathy or idiopathic distal sensory polyneuropathy~* Patient is able to complete questionnaires in either English or Spanish~* Patient is at least 18 years of age~Exclusion Criteria:~* Patient is either pregnant or breastfeeding~* Patient has a history of angioedema (swelling beneath the skin surface) or peripheral edema (foot, leg, and/or ankle swelling)~* Patient has a history of congestive heart failure~* Patient has a seizure disorder~* Patient has a history of drug and/or alcohol abuse within the past 1 year~* Patient failed treatment due to lack of pain relief with more than three drugs for nerve pain~* Patient has had cancer (except basal cell carcinoma) within the past two years~* Patient anticipates the need for surgery while participating in the study~* Patient has a reported history of hepatitis B, C, or HIV infection~* Patient has another type of pain that is more painful than the nerve pain~* Patient has generalized anxiety disorder, untreated depression, psychosis, or post-traumatic stress disorder~* Patient is involved in litigation or receives worker's compensation related to nerve pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Patients in Group A will remain on pregabalin (up to 600 mg/day po) treatment for the entire double-blind period.
- B (Type: PLACEBO_COMPARATOR): Patients in Group B will be treated with placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Chronic HCV-infected males and non-pregnant/non-lactating females~* Treatment-naïve or treatment-experienced individuals~* Compensated cirrhosis at Screening~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL (Type: EXPERIMENTAL): Participants received SOF/VEL (400/100 mg) orally once daily for up to 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
* Patients must have received either 2 or 3 prior chemotherapy regimens including adjuvant or neoadjuvant therapy.~* Prior treatment must have included both an anthracycline (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel).~* Patients must have received a minimum cumulative dose of anthracycline or must be resistant to an anthracycline.~* Patients must be resistant to taxane therapy.~* Patients may not have any history of brain and/or leptomeningeal metastases.~* Patients may not have CTC Grade 2 or greater neuropathy (motor or sensory).~* Patients may have not have had prior treatment with an epothilone and/or capecitabine (i.e., Xeloda)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete